Study guide

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD

Key Takeaways Explain This Topic AI

US low-risk drinking limits are no more than 4 drinks on any day and 14 per week for men, and no more than 3 on any day and 7 per week for women.

A US standard drink contains 14 grams of pure alcohol, equal to 12 ounces of 5% beer, 5 ounces of 12% wine, or 1.5 ounces of 80-proof spirits.

Brief intervention has its strongest evidence for unhealthy alcohol use that does not meet criteria for a disorder, and has repeatedly failed to change outcomes for drug use in primary care.

Reduced-drinking goals are legitimate treatment targets, and the WHO risk-drinking-level framework shows that dropping even one risk level produces measurable health benefit.

Prescribing non-pharmacological interventions using shared decision making is 14% of the CARN-AP blueprint, so imposing an abstinence goal on an ambivalent patient is both clinically and psychometrically the wrong answer.

Last updated: September 2026

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD

Quick Answer: A US standard drink is 14 grams of pure alcohol . Low-risk limits are no more than 4 drinks in a day and 14 per week for men , and no more than 3 in a day and 7 per week for women . Brief intervention is a 5- to 15-minute motivational conversation using FRAMES (Feedback, Responsibility, Advice, Menu, Empathy, Self-efficacy), most effective for unhealthy drinking that falls short of a disorder. For diagnosed alcohol use disorder, the drinking goal is negotiated, not imposed: reduced drinking is a legitimate target , and moving down even one WHO risk-drinking level produces measurable benefit.

1. The Arithmetic Patients Get Wrong

  • Beverage Volume Typical ABV Standard drinks
  • Regular beer 12 oz 5% 1
  • Malt liquor 8–9 oz 7% 1
  • Table wine 5 oz 12% 1
  • Distilled spirits, 80 proof 1.5 oz 40% 1
  • A 750 mL bottle of wine 25 oz 12% about 5
  • A 1.75 L handle of spirits 59 oz 40% about 39

Most patients underestimate consumption because home pours are larger than standard and because craft beer commonly runs 7 to 9% ABV. Walking through this table converts "a couple of glasses of wine" into a countable number — often the single most persuasive piece of feedback in a brief intervention.

2. FRAMES

Element What the APRN actually says

Feedback "Your AUDIT-C is 7. About 95% of adults your age drink less than you do, and your liver enzymes show the pattern."

  • Responsibility "What you do with that is entirely your call."
  • Advice "My clear medical advice is to cut down to under 7 drinks a week — or to stop."

Menu "Some people set a daily cap, some take three alcohol-free days a week, some try a month off, some use medication. Which of those sounds workable?"

  • Empathy "Most people who drink at this level have a real reason they started. I'm not here to lecture."
  • Self-efficacy "You quit smoking two years ago. That is exactly the skill this takes."

Boundary of the evidence: brief intervention reliably reduces drinking in people with unhealthy use short of a disorder . It has not produced consistent benefit for illicit drug use in primary care trials, and it is not adequate treatment for moderate-to-severe alcohol use disorder — those patients need treatment engagement and medication.

3. WHO Risk Drinking Levels

  • Level Men (grams/day) Women (grams/day)
  • Low risk 1–40 1–20
  • Medium risk 41–60 21–40
  • High risk 61–100 41–60
  • Very high risk over 100 over 60

A reduction of one or more risk levels is associated with improved liver enzymes, blood pressure and mortality. This gives the APRN an evidence-based way to honor a patient's reduced-drinking goal without abandoning the health target: "You are at very high risk right now. If we get you to high risk, your blood pressure and liver numbers will move. If we get you to medium, they'll move more."

4. Negotiating the Goal

Activity Area II-B — implement non-pharmacological interventions utilizing shared decision making — is 14% of the exam , and the highest-rated activity in it is "uses evidence-based treatments, therapies and procedures considering the healthcare consumer's comprehensive healthcare needs" (index 11.01), followed closely by "integrates the healthcare consumer's values, beliefs and preferences into the treatment plan."

When abstinence should be strongly recommended:

  • Pregnancy
  • Alcohol-associated liver disease, pancreatitis, or transplant candidacy
  • Prior withdrawal seizures or delirium tremens
  • Concurrent sedative or opioid use
  • Medication interactions such as disulfiram, or conditions worsened by any drinking

When a reduced-drinking goal is defensible:

  • Mild to moderate alcohol use disorder without the above
  • A patient who refuses abstinence and would otherwise disengage entirely
  • As a stepping stone, with an explicit re-evaluation date

Naltrexone in particular supports reduced-drinking goals — the targeted (Sinclair) approach , taking naltrexone before anticipated drinking, is an established harm-reduction protocol even though daily dosing is the labeled use.

5. Documenting the Conversation

A defensible note contains: the screening result and quantity/frequency data in standard drinks; the specific medical feedback given; the patient's stated goal in the patient's words; the options offered; the agreed plan including medication if accepted; the follow-up interval; and the specific conditions that would change the recommendation to abstinence. That last element is what protects both the patient and the APRN when a reduced-drinking goal is chosen.